Developing a long-lasting treatment for methamphetamine addiction
Official title: IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder
Funded at Intervexion Therapeutics, LLC · NIH-10890735 · Data updated 2026-11-12
This study is working on a new treatment for people with methamphetamine use disorder by developing a special antibody that can help lessen the effects of the drug, making it easier for them to stick to their recovery plan.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intervexion Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | September 30, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $4,314,989 |
| NIH project number | 5U01DA056240-03 |
| Project ID | NIH-10890735 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with methamphetamine use disorder who are seeking treatment.
✕Less likely to help
Patients who do not have a methamphetamine use disorder or those who are not seeking treatment may not benefit from this research.
What this research studies
This research focuses on creating a monoclonal antibody that can help treat methamphetamine use disorder (MUD) by reducing the drug's effects in the body. The approach involves developing a long-acting antibody that can be administered less frequently, potentially improving patient compliance with treatment. The research will include preclinical testing in animal models to identify the most effective antibody candidate before moving to human trials. If successful, this treatment could provide a new option for individuals struggling with MUD.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for individuals with methamphetamine use disorder.
How similar studies have gone: Previous research has shown promise with anti-METH antibodies in animal models, but this approach is still in the development phase for human application.
Where this research is happening
-
Intervexion Therapeutics, LLC
Little Rock, United States Active
Researchers
- Principal investigator: Stevens, Misty Ward — Intervexion Therapeutics, LLC
- Study coordinator: Stevens, Misty Ward
Related research
Other NIH-funded projects on the same topics.
-
Calming cue-triggered cravings in methamphetamine use
Seeing if teaching people with methamphetamine use disorder a thinking-based skill (cognitive reappraisal) can reduce brain and craving reactions to drug cues.
-
Psilocybin for treatment of methamphetamine use disorder
A study is testing whether psilocybin can help people with methamphetamine use disorder feel better and stay abstinent, starting with a small, carefully monitored group.
-
Reducing Methamphetamine Use to Improve Health and Well-Being
A clinical trial tests whether giving incentives to people with methamphetamine use disorder helps them use less meth and improves heart, immune, sleep, and psychosocial health.
-
Mobilizing Recovery Resources to Improve HIV Care for People Using Methamphetamine
A patient-friendly project to help people living with HIV who use methamphetamine strengthen personal and community supports to stay engaged in care.
-
Psilocybin-assisted therapy for methamphetamine use disorder in people with HIV
A small, carefully controlled study will test whether psilocybin, given with support, can help people living with HIV who have moderate-to-severe methamphetamine use disorder.
-
Tirzepatide for Methamphetamine Use Disorder in adults with diabetes
A study will test whether an approved diabetes drug, tirzepatide, helps adults with methamphetamine use disorder who have diabetes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.